Presentation is loading. Please wait.

Presentation is loading. Please wait.

Copyright © 2014 SCKCEN Production of medical radioisotopes at MYRRHA Lucia Popescu SCKCEN

Published byTiffany Jacobs Modified over 8 years ago

Similar presentations

Presentation on theme: "Copyright © 2014 SCKCEN Production of medical radioisotopes at MYRRHA Lucia Popescu SCKCEN"— Presentation transcript:

1 Copyright © 2014 SCKCEN Production of medical radioisotopes at MYRRHA Lucia Popescu SCKCEN lpopescu@sckcen.be

2 Copyright © 2014 SCKCEN Outline MYRRHA – Introduction Production of reactor-based medical radioisotopes The RIB facility: ISOL@MYRRHA Medical applications of ISOL@MYRRHA Conclusion 2L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

3 Copyright © 2014 SCKCEN MYRRHA - Accelerator Driven System Reactor Subcritical or Critical modes 65 to 100 MWth Accelerator (600 MeV - 4 mA proton) Fast Neutron Source Spallation Source Lead-Bismuth coolant Multipurpose Flexible Irradiation Facility 3 3L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

4 Copyright © 2014 SCKCEN 4L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA MYRRHA: EXPERIMENTAL ACCELERATOR DRIVEN SYSTEM A pan-European, innovative and unique facility 4

5 Copyright © 2014 SCKCEN Outline MYRRHA – Introduction Production of reactor-based medical radioisotopes The RIB facility: ISOL@MYRRHA Medical applications of ISOL@MYRRHA Conclusion 5L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

6 Copyright © 2014 SCKCEN Production of radioisotopes in MYRRHA thermal-neutron flux traps Core lay-out: In reflector positions Cooled by water In thermalized neutron field Transport by rabbit system Target plates in IPS: 6L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

7 Copyright © 2014 SCKCEN Radioisotope (Mo-99) production capability Sub-critical @ 73 MW Average specific power 173 W/cm 2 184 W/cm 2 171 W/cm 2 7L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

8 Copyright © 2014 SCKCEN Radioisotope (Mo-99) production capability Critical @ 100 MW Heat flux ≤ 400 W/cm 2 8L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

9 Copyright © 2014 SCKCEN Outline MYRRHA – Introduction Production of reactor-based medical radioisotopes The RIB facility: ISOL@MYRRHA Medical applications of ISOL@MYRRHA Conclusion 9L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

10 Copyright © 2014 SCKCEN ISOL@MYRRHA - Concept  ECR 1+  Surface IS  RILIS + liquid targets 10L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

11 Copyright © 2014 SCKCEN MYRRHA Accelerator Challenge fundamental parameters (ADS) particlep beam energy600 MeV beam current4 mA modeCW MTBF (failure = beam trip > 3 s) > 250 h implementation superconducting linac frequency176.1 / 352.2 / 704.4 MHz reliability = redundancydouble injector “fault tolerant” scheme challenge ! MYRRHA accelerator – high reliability => Extended runs with stable operation at I@M 11L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

12 Copyright © 2014 SCKCEN ISOL@MYRRHA Applications 12L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

13 Copyright © 2014 SCKCEN Outline MYRRHA – Introduction Production of reactor-based medical radioisotopes The RIB facility: ISOL@MYRRHA Medical applications of ISOL@MYRRHA Conclusion 13L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

14 Copyright © 2014 SCKCEN ISOL@MYRRHA - Medical Applications ISOL@MYRRHA can produce any radioisotope of medical interest (high purity!) However, ISOL is an “expensive” production technique ISOL@MYRRHA will focus mostly on innovative medical isotopes, that cannot be produced (with high purity) by classical methods Other idea for MRI production: harvesting the beam-dump 14L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

15 Copyright © 2014 SCKCEN ISOL@MYRRHA - Medical Applications Conventional cancer treatments: Surgery Radiation therapy Combination of radiation and surgery Chemotherapy Beginning of: Systematic radio-nuclide therapy Tumor-seeking tracer labeled with  emitter Range of  emitters: 30-80  m (cell surgery) Important criteria: Half-life Radio-toxicity of daughter isotopes Bio-kinetics (in-vivo stability of tumor- seeking tracer) Affordable production price Reliable supply Burkitt-lymphoma cancer study on mice: (G.J. Beyer et al., Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 547) Tumor-seeking tracer: Rituximab Radio-isotope: 149 Tb 70-kg patient sample (1 GBq): 0.6-GeV p + Ta: ~18 min/sample 1-GeV p + Ta: ~7 min/sample rough estimation 15L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

16 Copyright © 2014 SCKCEN ISOL@MYRRHA – Unique Facility Standard ISOL facility ISOL@MYRRHA Pure RIBs Intense RIBs Extra pure RIBs Extra intense RIBs Fundamental research Fundamental interactions Nuclear physics Atomic physics Biology Condensed matter +Radio-pharmaceuticals Long beam times Possible application Radio-pharmaceuticals SCKCEN Expertise Infrastructure UC x hp target develop. Molten-metal target develop. Hot-cell exp./infra. Radio-chemistry labs Radio-biology labs 16L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

17 Copyright © 2014 SCKCEN MYRRHA project schedule 2010-2014 Front End Engineering Design 2019 On site assembly 2016-2018 Construction of components & civil engineering 2015 Tendering & Procurement 2020-2022 Commissioning 2023 Progressive start-up 2024- Full exploitation FEED (Front End Engineering Design) Minimise technological risks Secure the licensing Secure a sound management and investment structure PDP preliminary dismantling plan PSAR preliminary safety assesment EIAR environmental impact assesment Central Project Team Owner Engineering Team Owner Consortium Group 2010-2014 17L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

18 Copyright © 2014 SCKCEN ISOL@MYRRHA Feasibility Study (pre-conceptual design and scientific case) carried out within BriX-IAP6 (2007-2012) Technical & Scientific report submitted to NuPECC  2010 – Technical Design of ISOL@MYRRHA included in the long- range plan of NuPECC Detailing the Design, updating the Scientific Case and building the Users Group through a series of topical workshops - BriX-IAP7 (2012-2017) ISOL@MYRRHA Project Belgian EURISOL Consortium (BEC) – founded in 2013, in support of EURISOL & ISOL@MYRRHA  Aim: Coordinated RTD programme – ISOL developments Joining EURISOL collaboration (MOU signed in July 2014) 18L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

19 Copyright © 2014 SCKCEN Conclusion MYRRHA-ADS Continue the 99 Mo production presently ensured by BR2 reactor Allow the development of an ISOL facility sharing the p-beam ISOL@MYRRHA RIBs production: High intensity ( ~ 100 x ISOLDE ) High purity High reliability (long beam times with stable operation) Unique experimental programme Capability for systematic production of MRIs developed at MEDICIS 19L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

20 Copyright © 2014 SCKCEN Copyright © 2014 - SCK  CEN PLEASE NOTE! This presentation contains data, information and formats for dedicated use ONLY and may not be copied, distributed or cited without the explicit permission of the SCKCEN. If this has been obtained, please reference it as a “personal communication. By courtesy of SCKCEN”. SCKCEN Studiecentrum voor Kernenergie Centre d'Etude de l'Energie Nucléaire Belgian Nuclear Research Centre Stichting van Openbaar Nut Fondation d'Utilité Publique Foundation of Public Utility Registered Office: Avenue Herrmann-Debrouxlaan 40 – BE-1160 BRUSSELS Operational Office: Boeretang 200 – BE-2400 MOL 20L. Popescu (SCKCEN) - Production of medical radioisotopes at MYRRHA

Download ppt "Copyright © 2014 SCKCEN Production of medical radioisotopes at MYRRHA Lucia Popescu SCKCEN"

Similar presentations

MYRRHA Injector at UCL Dirk Vandeplassche Luis Medeiros Romão SCK CEN MAX International Design Review Brussels, 12-13 November 2012 Dirk Vandeplassche,

MYRRHA Injector at UCL Dirk Vandeplassche Luis Medeiros Romão SCK CEN MAX International Design Review Brussels, November 2012 Dirk Vandeplassche,
Copyright © 2012 SCKCEN WP1: Reference design objectives and specifications Didier De Bruyn (SCKCEN), Presented by Alessandro Alemberti (ANS) 1 7th LEADER.

Copyright © 2012 SCKCEN WP1: Reference design objectives and specifications Didier De Bruyn (SCKCEN), Presented by Alessandro Alemberti (ANS) 1 7th LEADER.
Didier De Bruyn & Rafaël Fernandez (SCKCEN), Luigi Mansani (Ansaldo), Antony Woaye-Hune (AREVA), Massimo Sarotto (ENEA) & Evaldas Bubelis (KIT) ICAPP’12.

Didier De Bruyn & Rafaël Fernandez (SCKCEN), Luigi Mansani (Ansaldo), Antony Woaye-Hune (AREVA), Massimo Sarotto (ENEA) & Evaldas Bubelis (KIT) ICAPP’12.
HZDR FLUKA activities in support of the MYRRHA Project Short summary with a focus on activation problems Anna Ferrari, Stefan Müller, Jörg Konheiser.

HZDR FLUKA activities in support of the MYRRHA Project Short summary with a focus on activation problems Anna Ferrari, Stefan Müller, Jörg Konheiser.
SUPERCONDUCTING RF (SRF) SYSTEMS Peter McIntosh (STFC) Accelerator-driven Production of Medical Isotopes 8 th – 9 th December 2011 1.

SUPERCONDUCTING RF (SRF) SYSTEMS Peter McIntosh (STFC) Accelerator-driven Production of Medical Isotopes 8 th – 9 th December
EURISOL Transition period MYRRHA and

EURISOL Transition period MYRRHA and
Copyright © 2012 SCKCEN The MYRRHA Project Lucia Popescu SCKCEN

Copyright © 2012 SCKCEN The MYRRHA Project Lucia Popescu SCKCEN
Copyright © 2013 SCKCEN MAX School - Frankfurt am Main – 1 st -2 nd October 2013 MYRRHA Multipurpose hYbrid Research Reactor for High-tech Applications.

Copyright © 2013 SCKCEN MAX School - Frankfurt am Main – 1 st -2 nd October 2013 MYRRHA Multipurpose hYbrid Research Reactor for High-tech Applications.
MYRRHA Multipurpose hYbrid Research Reactor for High-tech Applications

MYRRHA Multipurpose hYbrid Research Reactor for High-tech Applications
A world of hope through accelerator- based science and technologies.

A world of hope through accelerator- based science and technologies.
MYRRHA ADS, What’s that ? and what for ?

MYRRHA ADS, What’s that ? and what for ?
1Jean-Luc Biarrotte, SPL/ESS meeting, Lünd, June 30, 2010. Accelerator design for MYRRHA J-L. Biarrotte, CNRS-IN2P3 / IPN Orsay.

1Jean-Luc Biarrotte, SPL/ESS meeting, Lünd, June 30, Accelerator design for MYRRHA J-L. Biarrotte, CNRS-IN2P3 / IPN Orsay.
Alex C. MUELLER Physics with a multi-MW proton source, CERN, Geneva, 25-27 May 20041 Additional Installations for a Nuclear Physics Facility Alex C. MUELLER.

Alex C. MUELLER Physics with a multi-MW proton source, CERN, Geneva, May Additional Installations for a Nuclear Physics Facility Alex C. MUELLER.
ADSR systems and their contribution to our energy needs Roger Barlow DIUS visit Manchester, 16 th September 2008.

ADSR systems and their contribution to our energy needs Roger Barlow DIUS visit Manchester, 16 th September 2008.
WP4: Applications of Accelerators

WP4: Applications of Accelerators
Copyright © 2014 SCKCEN EuCARD-2/MAX Accelerators for Accelerator Driven Systems Workshop – CERN, Switzerland – March 20 th –21 st 2014 MYRRHA Multipurpose.

Copyright © 2014 SCKCEN EuCARD-2/MAX Accelerators for Accelerator Driven Systems Workshop – CERN, Switzerland – March 20 th –21 st 2014 MYRRHA Multipurpose.
KIT – University of the State of Baden-Wuerttemberg and National Research Center of the Helmholtz Association Institute for Nuclear and Energy Technologies.

KIT – University of the State of Baden-Wuerttemberg and National Research Center of the Helmholtz Association Institute for Nuclear and Energy Technologies.
FFAG Fixed Field Alternating Gradient synchrotrons, FFAGs, combine some of the main advantages of both cyclotrons and synchrotrons:  Fixed magnetic field.

FFAG Fixed Field Alternating Gradient synchrotrons, FFAGs, combine some of the main advantages of both cyclotrons and synchrotrons:  Fixed magnetic field.
Copyright © 2012 SCKCEN 3 rd LEADER International workshop Pisa & Bologna, 4-7 September 2012 Didier De Bruyn (SCKCEN) 1 Different ADS concepts in the.

Copyright © 2012 SCKCEN 3 rd LEADER International workshop Pisa & Bologna, 4-7 September 2012 Didier De Bruyn (SCKCEN) 1 Different ADS concepts in the.
EURISOL DS Target Meeting, CERN, CHY.KADIMarch 10-11, 2005 1 EURISOL DS PROJECT Task#2: MULTI-MW TARGET 1st year planning Y. Kadi (AB/ATB) European Organization.

EURISOL DS Target Meeting, CERN, CHY.KADIMarch 10-11, EURISOL DS PROJECT Task#2: MULTI-MW TARGET 1st year planning Y. Kadi (AB/ATB) European Organization.

Similar presentations

Ads by Google